Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-12-07
DOI
https://doi.org/10.1200/jco-25-02477
Citations
2
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
3.25
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer Ann Woyach, Ching Ching Leow, Catherine C. Coombs, Lugui Qiu et al.
2 citations
Journal of Clinical Oncology
Chronic Lymphocytic Leukemia Research
3.25
article

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer Ann Woyach, Ching Ching Leow, Catherine C. Coombs, Lugui Qiu, Paula Cramer, Katharine L. Lewis, Marisa Hill, Tomasz Wróbel, Shuhua Yi, Lutz Jacobasch, Ross Baker, Naleen Raj Bhandari, Katherine Bao, Stéphane Leprêtre, Anna Panovská, Marcelo Capra, Alejandro Berkovits, Sebastian Grosicki, Richy Agajanian, Muhıt Özcan, William G. Wierda, Jarosław Czyż, Sílvia Ribeiro, Wojciech J. Jurczak, Kamel Laribi, Ki‐Seong Eom, Yuanyuan Bian, Amy S. Ruppert
article en
2 citations

Abstract

Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.

Journal of Clinical OncologyVol. 44(6)
The University of Texas MD Anderson Cancer Center (US), Ankara University (TR), Medical University of Silesia (PL), Eli Lilly (United States) (US), The University of Western Australia (AU), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), University of California, Irvine (US), Masaryk University (CZ), Sir Charles Gairdner Hospital (AU), Nicolaus Copernicus University (PL), Wroclaw Medical University (PL), Düsseldorf University Hospital (DE), Department of the Premier and Cabinet (AU), University Hospital Brno (CZ), Centre Hospitalier du Mans (FR), Oncology Institute of Hope and Innovation (US), Inria Chile (CL), Laboratoire National Henri Becquerel (FR), Institute of Hematology & Blood Diseases Hospital (CN), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), University Hospital Cologne (DE), Orthopädische Praxis (DE), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Hospital Mãe de Deus (BR), Heinrich Heine University Düsseldorf (DE), The Ohio State University (US)
Openalex Percentile: Top 7%
Chronic Lymphocytic Leukemia Research
3.25
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.